With the U.S. FDA’s approval of Enflonsia (cesrovimab) to prevent respiratory syncytial virus (RSV) infection lower ...

The FDA approved the monoclonal antibody clesrovimab-cfor for the prevention of respiratory syncytial virus lower respiratory ...

The United States could soon have another tool in the fight against respiratory syncytial virus, an illness that’s the No. 1 ...

The CDC’s Advisory Committee on Immunization Practices is expected to meet later in June to issue recommendations for use.

RSV hospitalization increases the likelihood of cardiovascular events, dysrhythmias or heart failure more than COVID-19 hospitalization.

Merck’s Enflonsia will go up against Sanofi and AstraZeneca’s Beyfortus, which the partners plan to ship out early in the ...

The U.S. Food and Drug Administration on Monday approved Merck's preventive antibody shot to protect infants up to one year ...

Merck (NYSE:MRK) has received FDA approval for Enflonsia, a prophylactic antibody therapy designed to protect infants from ...

This retrospective, observational study focused on adult patients (age ≥ 18 years) hospitalized with a diagnosis of lower respiratory tract infections during the influenza A (H1N1) pdm09 virus ...

ucl.ac.uk Respiratory syncytial virus (RSV) is the most common single cause of respiratory hospitalisation of infants and is the second largest cause of lower respiratory infection mortality worldwide ...